FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
17.25
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NeoGenomics, Inc. - Common Stock
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
Why NeoGenomics Stock Is Plunging Today
↗
March 29, 2022
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
↗
March 29, 2022
BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 29, 2022
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million.
Via
Benzinga
Where NeoGenomics Stands With Analysts
↗
March 29, 2022
Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
↗
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 10, 2022
↗
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
Recap: NeoGenomics Q4 Earnings
↗
February 23, 2022
NeoGenomics (NASDAQ:NEO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
↗
March 29, 2022
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
March 29, 2022
Good morning! It's time to start another busy day of trading with another breakdown of the biggest pre-market stock movers on Tuesday!
Via
InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
March 28, 2022
From
The Schall Law Firm
Via
Business Wire
Where NeoGenomics Stands With Analysts
↗
January 12, 2022
Over the past 3 months, 6 analysts have published their opinion on NeoGenomics (NASDAQ:
Via
Benzinga
SHAREHOLDER ALERT - Labaton Sucharow Investigating NeoGenomics Inc. - NEO
March 28, 2022
From
Labaton Sucharow LLP
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
March 28, 2022
Gainers NexImmune (NASDAQ:NEXI) stock moved upwards by 8.3% to $3.51 during Monday's after-market session. This security traded at a volume of 109.1K shares come close, making up 76.6% of its average...
Via
Benzinga
NeoGenomics Announces CEO Departure and Initiates CEO Search
March 28, 2022
Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc....
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
March 17, 2022
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Earnings Perspective: Return On Capital Employed
↗
March 14, 2022
NeoGenomics (NASDAQ:NEO) brought in sales totaling $125.73 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 105.22%, resulting in a loss...
Via
Benzinga
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
March 02, 2022
FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
From
NeoGenomics, Inc.
Via
AccessWire
10 Biggest Price Target Changes For Thursday
↗
February 24, 2022
SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
↗
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
February 23, 2022
Recent Highlights: - Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% - Fourth quarter consolidated revenue...
From
NeoGenomics, Inc.
Via
AccessWire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
↗
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Earnings Scheduled For February 23, 2022
↗
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
Dash, Amp Among Top Crypto Movers In 24H
↗
February 18, 2022
After pulling data from Benzinga Pro the following is the list of top crypto gainers an...
Via
Benzinga
Celsius Network, NEO Among Top Crypto Movers In 24H
↗
February 16, 2022
According to Benzinga Pro, the following are the crypto gainers and losers at the time ...
Via
Benzinga
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
February 14, 2022
FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
February 11, 2022
RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrence FT MYERS, FL / ACCESSWIRE / February 11, 2022 / NeoGenomics, Inc....
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
February 08, 2022
FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
February 02, 2022
FT MYERS, FL / ACCESSWIRE / February 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
January 24, 2022
The partnership makes it possible for patients with specific biomarkers to get early support FT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 11, 2022
FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
